CMS certification 050262
Ronald Reagan UCLA Medical Center
757 Westwood Plaza, Los Angeles, CA 90095
Ronald Reagan UCLA Medical Center has a CMS overall rating of 4 out of 5 stars. 79% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 25 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 5 and worse on 1. Emergency patients spend a median of 5 h 12 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 814 completed surveys, 18% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | CA | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 322 visits sampled · US median for EDs of the same volume: 3 h 22 min | 5 h 12 min | 2 h 54 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 44 visits sampled | 9 h 1 min | 4 h 20 min | 4 h 17 min |
| Left before being seen Lower is better · 56,691 patients | 5% | 2% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 97 patients | 74% | 70% | 65% |
How Ronald Reagan UCLA Medical Center compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| Ronald Reagan UCLA Medical CenterThis hospital | 4/5 | 79% | 5 h 12 min | 5 better 1 worse |
| VA Greater Los Angeles Healthcare SystemSame city | 3/5 | 66% | — | 2 better 4 worse |
| Martin Luther King, Jr. Community HospitalSame city | 4/5 | 68% | 2 h 30 min | 3 better 1 worse |
| Cedars-Sinai Medical CenterSame city | 5/5 | 78% | 5 h 55 min | 14 better 3 worse |
| Docs Surgical HospitalSame city | Not rated | 72% | — | No different |
| Kaiser Foundation Hospital - West LaSame city | 3/5 | 73% | — | 1 better 1 worse |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Los Angeles.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 3,004 cases | Too few cases | 2.4% | 3.9% |
| Heart attack 107 cases | Too few cases | 9.5% | 11.9% |
| Heart failure 350 cases | Too few cases | 7.9% | 11.1% |
| Pneumonia 436 cases | Too few cases | 11.1% | 15.2% |
| Stroke 242 cases | Too few cases | 12.8% | 11.9% |
| COPD 49 cases | Too few cases | 7.2% | 8.6% |
| Heart bypass surgery (CABG) 122 cases | Too few cases | 2.1% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 0.9 likely 0.7 – 1.09 | 1 |
| Deaths after a serious but treatable surgical complication 282 cases | No different | 171.14 per 1,000 likely 139.88 per 1,000 – 202.41 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 8,165 cases | Better | 0.21 per 1,000 likely 0 per 1,000 – 0.62 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 9,102 cases | No different | 0.16 per 1,000 likely 0 per 1,000 – 0.34 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 10,460 cases | No different | 0.27 per 1,000 likely 0.09 per 1,000 – 0.44 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 3,000 cases | No different | 2.36 per 1,000 likely 1.27 per 1,000 – 3.44 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 1,972 cases | No different | 1.67 per 1,000 likely 0.57 per 1,000 – 2.77 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 1,778 cases | Better | 5.17 per 1,000 likely 1.78 per 1,000 – 8.56 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 3,570 cases | Worse | 6.27 per 1,000 likely 4.69 per 1,000 – 7.85 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 2,101 cases | No different | 5.93 per 1,000 likely 3.76 per 1,000 – 8.09 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 1,032 cases | No different | 2.65 per 1,000 likely 1.31 per 1,000 – 3.98 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 2,883 cases | No different | 0.67 per 1,000 likely 0 per 1,000 – 1.44 per 1,000 | 1.06 per 1,000 |
1 more measure had too few cases here to report.
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | Better | 0.61 likely 0.43 – 0.84 | 1 |
| Urinary tract infections from catheters (CAUTI) | Better | 0.59 likely 0.38 – 0.87 | 1 |
| Surgical site infections after colon surgery | No different | 0.63 likely 0.23 – 1.39 | 1 |
| Surgical site infections after abdominal hysterectomy | No different | 0 | 1 |
| MRSA bloodstream infections | No different | 0.56 likely 0.26 – 1.06 | 1 |
| C. diff intestinal infections | Better | 0.5 likely 0.36 – 0.69 | 1 |
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 138 cases | Too few cases | 14.8% | 14.4% |
| Readmitted after heart failure 357 cases | Too few cases | 19.9% | 21.3% |
| Readmitted after pneumonia 404 cases | Too few cases | 17.1% | 17.3% |
| Readmitted after COPD 49 cases | Too few cases | 19.8% | 20% |
| Readmitted after heart bypass surgery 119 cases | Too few cases | 10.8% | 11% |
| Days back in hospital after a heart attack 122 cases | Too few cases | -7.1 days per 100 | — |
| Days back in hospital after heart failure 385 cases | Too few cases | -12.9 days per 100 | — |
| Days back in hospital after pneumonia 427 cases | Too few cases | 13.6 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 2,701 cases | No different | 10.8 per 1,000 likely 8.5 per 1,000 – 13.7 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 609 cases | No different | 12.3 per 100 likely 10.1 per 100 – 15 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 609 cases | No different | 4.9 per 100 likely 3.7 per 100 – 6.5 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 1,463 cases | No different | 0.9 likely 0.8 – 1.1 | — |
2 more measures had too few cases here to report.
Clinicians registered at this address
1,351 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 855 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Anesthesiology | 277 |
| Diagnostic Radiology | 221 |
| Hospitalist | 116 |
| Internal Medicine | 94 |
| Emergency Medicine | 93 |
| Nurse Anesthetist, Certified Registered | 71 |
| Pediatrics | 62 |
| Acute Care | 48 |
| Nurse Practitioner | 35 |
| Vascular & Interventional Radiology | 31 |
| Pharmacist | 30 |
| Emergency Medical Services | 28 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $32.9M
- 2020 $36.7M
- 2021 $28.2M
- 2022 $33.8M
- 2023 $36.2M
- 2024 $41.4M
- 2025 $41.5M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Royalties and licensing fees | $1.3M | 24 |
| Grants | $893,484 | 46 |
| Space rental and facility fees | $759,075 | 71 |
| Speaking, teaching and other services | $705,123 | 20 |
| Medical devices and supplies on long-term loan | $153,365 | 10 |
| Education | $67,661 | 5 |
| Debt forgiveness | $36,519 | 42 |
| Charitable contributions | $2,750 | 2 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Merck Sharp & Dohme LLC | $6M | 84 |
| AstraZeneca Pharmaceuticals LP | $3.1M | 36 |
| Amgen Inc. | $2.5M | 36 |
| Abbvie INC. | $2.2M | 79 |
| Genentech, Inc. | $2.1M | 105 |
| Pfizer INC. | $1.9M | 141 |
| Novartis Pharmaceuticals Corporation | $1.5M | 25 |
| Eli Lilly and Company | $1.3M | 31 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib and Venetoclax in patients with previously untreated follicular Lymphoma ABBVIE INC. · NCT04450173 | $1.5M |
| An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatini… Merck Sharp & Dohme LLC | $1.3M |
| STUDY NAME#Neoadjuvant Combination Pembrolizumab , Enfortumab Vedotin with Adjuvant Pembrolizumab Prior to and After Radical Nephroureterectomy for H… Merck Sharp & Dohme LLC | $993,315 |
| A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Re… Celgene Corporation | $811,173 |
| A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With … Amgen Inc. | $699,203 |
| DS1062-A-J101 Daiichi Sankyo Inc. · NCT03401385 | $694,530 |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309) Amgen Inc. | $679,019 |
| Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin Prior to Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma Astellas US Technologies | $652,407 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Ronald Reagan UCLA Medical Center
Is Ronald Reagan UCLA Medical Center a good hospital?
Ronald Reagan UCLA Medical Center has a CMS overall rating of 4 out of 5 stars. Of the 25 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 5 and worse on 1. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Ronald Reagan UCLA Medical Center?
79% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 814 completed HCAHPS surveys.
How long is the wait in the Ronald Reagan UCLA Medical Center emergency room?
Emergency patients spend a median of 5 h 12 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with high patient volume, like this one, the median is 3 h 22 min. 5% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does Ronald Reagan UCLA Medical Center receive money from drug and device companies?
Drug and device makers reported $41.5M in payments to Ronald Reagan UCLA Medical Center for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.